Trial Profile
A single-center, randomised, crossover phase I study to assess the safety, tolerability and pharmacokinetics of the two new oral THC and CBD formulations in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Dec 2016
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary) ; Tetrahydrocannabinol (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Pharmacokinetics
- 29 Dec 2016 New trial record